Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles.

Although virus infections have been classically studied with "cell-free" virion preparations, many animal viruses are able to spread both in vitro and in vivo by inducing cell-cell fusion. An efficient system to monitor the cell-to-cell spread of HIV-1 has been developed employing chronically infected H9 donor cells. Under appropriate conditions of cocultivation with uninfected cells, the synthesis of unintegrated viral DNA, monitored by Southern blot hybridization, occurred between 2 and 4 hr following infection; viral proteins were detected 8 to 12 hr following cocultivation and progeny virions were released into the medium by 16 hr. The use of metabolic inhibitors or specific envelope/receptor antibodies revealed that the cell-to-cell spread of HIV required: (1) gp120-CD4 interaction and (2) reverse transcription. Light and electron microscopy, fluorescent dye redistribution, and soluble CD4 competition experiments all demonstrated that the HIV-induced cell-cell fusion began within 10 to 30 min of cocultivation. Surprisingly, the electron microscopic analyses also suggested that budding or mature virus particles did not participate in this process. Thus the virus-induced cell-cell fusion observed is very likely the result of gp120/gp41 proteins, on the surface of infected cells, interacting with CD4 molecules on uninfected cells. These findings are of immediate importance in understanding the mechanism(s) of HIV-1 transmission in vivo and for the design of effective vaccines and antiviral agents.

[1]  T. Klimkait,et al.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release , 1990, Journal of virology.

[2]  W. Plunkett,et al.  Selective action of 3'-azido-3'-deoxythymidine 5'-triphosphate on viral reverse transcriptases and human DNA polymerases. , 1990, The Journal of biological chemistry.

[3]  Y. Okada,et al.  Morphological changes in Ehrlich ascites tumor cells during the cell fusion reaction with HVJ (Sendai Virus). I. Alterations of cytoplasmic organelles and their reversion. , 1980, Experimental cell research.

[4]  G. Henle,et al.  Cytolytic Effects of Mumps Virus in Tissue Cultures of Epithelial Cells.∗ , 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[5]  P. Earl,et al.  In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity , 1988, Journal of virology.

[6]  K. Steimer,et al.  Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein , 1986, Nature.

[7]  J. Levy,et al.  Recovery of human immunodeficiency virus from serum. , 1987, JAMA.

[8]  H. Lazarus,et al.  Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia , 1965, Cancer.

[9]  T. Uryu,et al.  Sulfation of polysaccharides generates potent and selective inhibitors of human immunodeficiency virus infection and replication in vitro. , 1987, Japanese journal of cancer research : Gann.

[10]  B. Oberg,et al.  Inhibition of HTLV-III/LAV replication by foscarnet. , 1985, Biochemical pharmacology.

[11]  K. Strebel,et al.  The HIV A (sor) gene product is essential for virus infectivity , 1987, Nature.

[12]  Charles F. Johnson,et al.  Cytological Studies of Newcastle Disease Virus (NDV) in HEp-2 Cells.∗ , 1964, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[13]  A. Notkins,et al.  Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection , 1976, Infection and immunity.

[14]  H. Gendelman,et al.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone , 1986, Journal of virology.

[15]  A. Collier,et al.  Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[16]  J. Enders,et al.  Propagation in Tissue Cultures of Cytopathogenic Agents from Patients with Measles.† , 1954, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[17]  Y. Okada,et al.  Morphological changes in Ehrlich ascites tumor cells during the cell fusion reaction with HVJ (Sendai virus). II. Cluster formation of intramembrane particles in the early stage of cell fusion. , 1981, Experimental cell research.

[18]  Y. Okada Chapter 10 Sendai Virus-Mediated Cell Fusion , 1988 .

[19]  A. Fisher,et al.  The sor gene of HIV-1 is required for efficient virus transmission in vitro. , 1987, Science.

[20]  A. Notkins,et al.  PREVENTION OF CELL-TO-CELL SPREAD OF HERPES SIMPLEX VIRUS BY LEUKOCYTES , 1973, The Journal of experimental medicine.

[21]  E. De Clercq,et al.  Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. , 1990, Virology.

[22]  T. Taguchi,et al.  Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-α , 1978, Nature.

[23]  E. De Clercq,et al.  Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. , 1987, Antiviral research.

[24]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[25]  R. Cheynier,et al.  LAV revisited: origins of the early HIV-1 isolates from Institut Pasteur. , 1991, Science.

[26]  B. Oberg,et al.  Phosphonoformate inhibits reverse transcriptase. , 1979, The Journal of general virology.

[27]  A. Venet,et al.  Correlation between CD4 cell counts and cellular and plasma viral load in HIV-1-seropositive individuals. , 1991, AIDS.

[28]  R. Weiss,et al.  Productive infection and cell-free transmission of human T-cell leukemia virus in a nonlymphoid cell line. , 1983, Science.

[29]  B. Sundquist,et al.  Phosphonoformate inhibition of visna virus replication , 1979, Journal of virology.

[30]  K. Sell,et al.  Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Ueno,et al.  DEXTRAN SULPHATE, A POTENT ANTI-HIV AGENT IN VITRO HAVING SYNERGISM WITH ZIDOVUDINE , 1987, The Lancet.

[32]  A. Scheid,et al.  Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection , 1980, Journal of Experimental Medicine.

[33]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[34]  J. Albert,et al.  REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.

[35]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[36]  L. Callahan,et al.  Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions , 1991, Journal of virology.

[37]  F. Sala,et al.  Aphidicolin: a specific inhibitor of nuclear DNA replication in eukaryotes , 1982 .

[38]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  B. Roizman,et al.  The isolation and properties of a variant of Herpes simplex producing multinucleated giant cells in monolayer cultures in the presence of antibody. , 1959, American journal of hygiene.

[40]  A. Fauci,et al.  Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. , 1986, Science.

[41]  B. Hirt Selective extraction of polyoma DNA from infected mouse cell cultures. , 1967, Journal of molecular biology.

[42]  MartinS. Hirsch,et al.  INHIBITION OF HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE III IN VITRO BY PHOSPHONOFORMATE , 1985, The Lancet.

[43]  J. Albert,et al.  Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates , 1988, Journal of virology.

[44]  S. O’Brien,et al.  Origin of the HIV-susceptible human CD4+ cell line H9. , 1989, AIDS research and human retroviruses.

[45]  Huisman,et al.  Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex , 1988, Journal of virology.

[46]  J. Spouge,et al.  Blocking of human immunodeficiency virus infection depends on cell density and viral stock age , 1991, Journal of virology.

[47]  J. Huberman New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase α , 1981, Cell.

[48]  J. Levy,et al.  Differential ability of human immunodeficiency virus isolates to productively infect human cells. , 1987, Journal of immunology.

[49]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[50]  F. Black,et al.  Microepidemiology of poliomyelitis and herpes-B infections: spread of the viruses within tissue cultures. , 1955, Journal of immunology.